A Phase 2 interventional study of Faricimab and Ranibizumab in Neovascularization, Choroidal and Macular Degeneration, Age-Related, sponsored by Hoffmann-La Roche. Completed at 25 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-01-05.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Choroidal Neovascularization with a site in United States — 2 open to participants now, 9 under way, 4 of them phase 3. Choroidal Neovascularization · United States.
Among the 88 studies in Choroidal Neovascularization with a site in United States, this one is the 29th largest by enrollment of the 77 interventional ones that give a count, is one of 3 that started in 2017, is one of 23 in phase 2, and was the 74th registered.
214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.
Browse Choroidal Neovascularization studies →2 of the 88 studies in Choroidal Neovascularization with a site in United States are open now. Recruiting first, the newest first:
EyeBiotech Ltd. · Sites in United States, Brazil, Colombia and 6 more countries
Ages 50+
EyeBiotech Ltd. · Sites in United States, Argentina, Australia and 9 more countries
Ages 50+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 37 · Phase 3 18 · Phase 4 4
First in 1997; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is above the median of 56 across 160 interventional studies indexed under Choroidal Neovascularization.
Median enrollment 42 across the 77 interventional studies, 77 across the 11 observational. Of the 75 that completed or were terminated, 32 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 88 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 5 studies filed under Choroidal Neovascularization — fewer than ten, so there is no comparison to draw.
2 of the studies in Choroidal Neovascularization with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
| NCT06125977University of UtahImpact of Non-Exudative Type 1 MNV on AMD Progression | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 88 studies in Choroidal Neovascularization with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a Phase II, multicenter, randomized, active comparator-controlled, 52-week study to investigate the efficacy, safety and pharmacokinetics of faricimab (RO6867461; RG7716) administered with extended dosing regimens in treatment-naive participants with neovascular age related macular degeneration (nAMD). Only one eye was chosen as the study eye.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6 mg faricimab was given by intravitreal (IVT) injection once every 4 weeks (Q4W) up to Week 12 (4 injections), followed by 6 mg faricimab IVT injection once every 12 weeks (Q12W) from Week 24 up to Week 48 (injections at Weeks 24, 36, and 48; 3 injections).
Drug: Faricimab · Drug: Sham Procedure
6 mg faricimab was administered by IVT injection once every 4 weeks (Q4W) up to Week 12 (4 injections), followed by no doses up to Week 24 when a protocol-defined assessment of disease activity was performed. Participants with disease activity at Week 24 initiated 6 mg faricimab IVT Q12W dosing, and participants without disease activity at Week 24 initiated 6 mg faricimab IVT once every 16 weeks (Q16W) dosing for the remainder of the study.
Drug: Faricimab · Drug: Sham Procedure
0.5 mg of ranibizumab was administered by IVT injection once every 4 weeks (Q4W) for 48 weeks (13 injections).
Drug: Ranibizumab
Faricimab was administered via IVT injections as specified during the treatment period.
Also known as: RO6867461, RG7716
Ranibizumab was administered via IVT injections as specified during the treatment period.
Also known as: Lucentis®
The sham was a procedure that mimicked an IVT injection and involved the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in the faricimab treatments arms at applicable visits to maintain masking among treatment arms.
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 40, Using the Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA Charts
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline BCVA.
Time frame: Baseline, Week 40
Mean Change From Baseline in BCVA at Specified Timepoints, Using the ETDRS BCVA Charts
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline BCVA.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Number and Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants Gaining ≥15 Letters From Baseline in BCVA at Specified Timepoints
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Number and Percentage of Participants Not Losing ≥15, ≥10, ≥5, or ≥0 Letters From Baseline in BCVA at Specified Timepoints
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a loss in BCVA letter score from baseline indicates worsening in visual acuity. This analysis was performed on observed data.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants Not Losing ≥15 Letters From Baseline in BCVA at Specified Timepoints
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Specified Timepoints
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Specified Timepoints
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Mean Change From Baseline in Central Foveal Thickness (CFT) at Specified Timepoints
Central foveal thickness (CFT) was defined as the thickness from the inner limiting membrane to the retinal pigment epithelial at the horizontal slice closest to the center of the fovea, and it was measured using spectral domain optical coherence tomography (SD-OCT). The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline CFT.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Mean Change From Baseline in Central Subfield Thickness (CST) at Specified Timepoints
Central subfield thickness (CST) was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 millimetre (mm) central subfield, and it was measured using spectral domain optical coherence tomography (SD-OCT). The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline CST.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants With No Intraretinal Fluid at Specified Timepoints
The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Intraretinal fluid was defined as the presence of fluid within the retina. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants With No Subretinal Fluid at Specified Timepoints
The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Subretinal fluid was defined as the presence of fluid between the retina and the retinal pigment epithelium. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants With No Cysts at Specified Timepoints
The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Cysts were defined as the presence of cystoid space (fluid) in the retina. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Percentage of Participants With No Pigment Epithelial Detachment at Specified Timepoints
The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Pigment epithelial detachment was defined as the presence of a detachment of the pigment epithelium from the Bruch's membrane. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
Time frame: Baseline, Day 7, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Mean Baseline Value and Mean Change From Baseline of Total Area of Choroidal Neovascularization (CNV) at Week 40 and Week 52
The total area of choroidal neovascularization (CNV) was evaluated by a central reading center using fundus fluorescein angiography (FFA).
Time frame: Baseline, Week 40, Week 52
Mean Baseline Value and Mean Change From Baseline of Total Area of CNV Component at Week 40 and Week 52
The total area of choroidal neovascularization (CNV) component (i.e., total area of CNV membrane) was evaluated by a central reading center using fundus fluorescein angiography (FFA).
Time frame: Baseline, Week 40, Week 52
Mean Baseline Value and Mean Change From Baseline of Total Area of Leakage at Week 40 and Week 52
The total area of leakage was evaluated by a central reading center using fundus fluorescein angiography (FFA).
Time frame: Baseline, Week 40, Week 52
Change From Baseline in the Number of Participants With Anti-Drug Antibodies (ADA) to Faricimab at Anytime Post-Baseline
Blood samples were obtained for measurement of anti-drug antibodies (ADAs) to faricimab by a validated enzyme-linked immunosorbent assay (ELISA).
Time frame: Predose at Baseline (Day 1), Weeks 16, 24, 28, 44, and 52
Safety Summary: Number and Percentage of Participants With at Least One Adverse Event
This safety summary reports the number and percentage of participants who experienced at least one adverse event (AE) during the study. The investigator independently assessed the seriousness and severity for each AE. Severity was graded according to the following grading scale: Mild = Discomfort noticed, but no disruption of normal daily activity; Moderate = Discomfort sufficient to reduce or affect normal daily activity; Severe = Incapacitating with inability to work or to perform normal daily activity. Severity and seriousness are not synonymous; regardless of severity, some AEs may have also met seriousness criteria.
Time frame: From Baseline until 28 days after the last dose of study drug (up to 52 weeks)
| Milestone | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W |
|---|---|---|---|
| Started | 24 | 31 | 16 |
| Completed | 21 | 28 | 16 |
| Not completed | 3 | 3 | 0 |
| Withdrew: Death | 1 | 2 | 0 |
| Withdrew: Physician decision | 2 | 1 | 0 |
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline BCVA.
| ETDRS Letters | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W |
|---|---|---|---|
| Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 40, Using the Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA Charts | 9.3 (6.4 to 12.3) | 12.5 (9.9 to 15.1) | 11.4 (7.8 to 15.0) |
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline BCVA.
| ETDRS Letters | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W |
|---|---|---|---|
| Day 7 | 3.78 (2.33 to 5.24) | 4.62 (3.33 to 5.91) | 3.53 (1.74 to 5.33) |
| Week 4 | 5.99 (4.10 to 7.88) | 7.55 (5.88 to 9.22) | 7.53 (5.21 to 9.86) |
| Week 8 | 5.28 (2.88 to 7.69) | 9.15 (7.01 to 11.29) | 10.55 (7.55 to 13.54) |
| Week 12 | 7.31 (4.87 to 9.75) | 10.19 (8.04 to 12.34) | 9.91 (6.94 to 12.88) |
| Week 16 | 8.31 (5.93 to 10.68) | 11.62 (9.52 to 13.71) | 10.78 (7.89 to 13.68) |
| Week 20 | 8.02 (5.35 to 10.69) | 10.40 (8.05 to 12.76) | 11.53 (8.28 to 14.78) |
| Week 24 | 8.11 (5.53 to 10.69) | 10.37 (8.10 to 12.65) | 10.97 (7.83 to 14.11) |
| Week 28 | 9.59 (7.06 to 12.12) | 11.82 (9.59 to 14.05) | 12.16 (9.08 to 15.23) |
| Week 32 | 9.87 (7.21 to 12.53) | 12.44 (10.10 to 14.79) | 11.91 (8.67 to 15.14) |
| Week 36 | 9.01 (6.14 to 11.87) | 12.38 (9.86 to 14.90) | 12.03 (8.57 to 15.50) |
| Week 40 | 9.33 (6.37 to 12.29) | 12.47 (9.86 to 15.08) | 11.42 (7.83 to 15.01) |
| Week 44 | 9.38 (6.42 to 12.34) | 12.07 (9.48 to 14.67) | 11.22 (7.65 to 14.79) |
| Week 48 | 9.53 (6.51 to 12.55) | 10.99 (8.33 to 13.64) | 10.22 (6.57 to 13.86) |
| Week 52 | 10.08 (7.05 to 13.12) | 11.42 (8.75 to 14.09) | 9.59 (5.93 to 13.25) |
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data.
| Participants | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W |
|---|---|---|---|
| Day 7: Gaining ≥15 Letters | 1 | 2 | 1 |
| Day 7: Gaining ≥10 Letters | 2 | 4 | 1 |
| Day 7: Gaining ≥5 Letters | 11 | 16 | 6 |
| Day 7: Gaining ≥0 Letters | 20 | 26 | 15 |
| Week 4: Gaining ≥15 Letters | 3 | 4 | 3 |
| Week 4: Gaining ≥10 Letters | 5 | 8 | 5 |
| Week 4: Gaining ≥5 Letters | 15 | 19 | 8 |
| Week 4: Gaining ≥0 Letters | 20 | 30 | 15 |
| Week 8: Gaining ≥15 Letters | 3 | 5 | 6 |
| Week 8: Gaining ≥10 Letters | 7 | 10 | 8 |
| Week 8: Gaining ≥5 Letters | 14 | 26 | 10 |
| Week 8: Gaining ≥0 Letters | 21 | 28 | 15 |
| Week 12: Gaining ≥15 Letters | 2 | 7 | 3 |
| Week 12: Gaining ≥10 Letters | 8 | 16 | 7 |
| Week 12: Gaining ≥5 Letters | 15 | 23 | 11 |
| Week 12: Gaining ≥0 Letters | 19 | 29 | 15 |
| Week 16: Gaining ≥15 Letters | 4 | 9 | 3 |
| Week 16: Gaining ≥10 Letters | 10 | 16 | 8 |
| Week 16: Gaining ≥5 Letters | 16 | 27 | 13 |
| Week 16: Gaining ≥0 Letters | 21 | 29 | 16 |
| Week 20: Gaining ≥15 Letters | 4 | 10 | 3 |
| Week 20: Gaining ≥10 Letters | 10 | 17 | 9 |
| Week 20: Gaining ≥5 Letters | 16 | 22 | 14 |
| Week 20: Gaining ≥0 Letters | 20 | 26 | 16 |
| Week 24: Gaining ≥15 Letters | 4 | 8 | 4 |
| Week 24: Gaining ≥10 Letters | 9 | 16 | 9 |
| Week 24: Gaining ≥5 Letters | 15 | 22 | 12 |
| Week 24: Gaining ≥0 Letters | 19 | 27 | 15 |
| Week 28: Gaining ≥15 Letters | 6 | 12 | 5 |
| Week 28: Gaining ≥10 Letters | 13 | 15 | 9 |
| Week 28: Gaining ≥5 Letters | 16 | 24 | 11 |
| Week 28: Gaining ≥0 Letters | 21 | 27 | 16 |
| Week 32: Gaining ≥15 Letters | 7 | 11 | 6 |
| Week 32: Gaining ≥10 Letters | 11 | 18 | 9 |
| Week 32: Gaining ≥5 Letters | 17 | 27 | 11 |
| Week 32: Gaining ≥0 Letters | 22 | 28 | 15 |
| Week 36: Gaining ≥15 Letters | 7 | 11 | 6 |
| Week 36: Gaining ≥10 Letters | 10 | 20 | 10 |
| Week 36: Gaining ≥5 Letters | 15 | 24 | 12 |
| Week 36: Gaining ≥0 Letters | 19 | 25 | 15 |
| Week 40: Gaining ≥15 Letters | 8 | 11 | 5 |
| Week 40: Gaining ≥10 Letters | 11 | 18 | 8 |
| Week 40: Gaining ≥5 Letters | 15 | 24 | 10 |
| Week 40: Gaining ≥0 Letters | 17 | 27 | 13 |
| Week 44: Gaining ≥15 Letters | 7 | 13 | 6 |
| Week 44: Gaining ≥10 Letters | 12 | 15 | 9 |
| Week 44: Gaining ≥5 Letters | 13 | 26 | 11 |
| Week 44: Gaining ≥0 Letters | 15 | 27 | 13 |
| Week 48: Gaining ≥15 Letters | 7 | 10 | 6 |
| Week 48: Gaining ≥10 Letters | 12 | 17 | 10 |
| Week 48: Gaining ≥5 Letters | 15 | 20 | 11 |
| Week 48: Gaining ≥0 Letters | 18 | 26 | 12 |
| Week 52: Gaining ≥15 Letters | 7 | 13 | 6 |
| Week 52: Gaining ≥10 Letters | 11 | 17 | 9 |
| Week 52: Gaining ≥5 Letters | 14 | 23 | 9 |
| Week 52: Gaining ≥0 Letters | 17 | 26 | 13 |
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
| Percentage of participants | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W |
|---|---|---|---|
| Day 7 | 4.2 (0.00 to 9.39) | 6.5 (0.80 to 12.11) | 6.3 (0.00 to 14.01) |
| Week 4 | 12.5 (3.85 to 21.15) | 12.9 (5.19 to 20.62) | 18.8 (6.24 to 31.26) |
| Week 8 | 12.5 (3.85 to 21.15) | 16.7 (7.95 to 25.39) | 40.0 (23.79 to 56.21) |
| Week 12 | 8.7 (1.17 to 16.23) | 23.3 (13.44 to 33.23) | 18.8 (6.24 to 31.26) |
| Week 16 | 17.4 (7.26 to 27.52) | 30.0 (19.28 to 40.72) | 18.8 (6.24 to 31.26) |
| Week 20 | 17.4 (7.26 to 27.52) | 33.3 (22.30 to 44.36) | 18.8 (6.24 to 31.26) |
| Week 24 | 17.4 (7.26 to 27.52) | 26.7 (16.32 to 37.01) | 25.0 (11.13 to 38.87) |
| Week 28 | 26.1 (14.35 to 37.82) | 40.0 (28.54 to 51.46) | 31.3 (16.40 to 46.10) |
| Week 32 | 30.4 (18.14 to 42.73) | 36.7 (25.39 to 47.94) | 37.5 (21.99 to 53.01) |
| Week 36 | 31.8 (19.09 to 44.54) | 37.9 (26.38 to 49.48) | 37.5 (21.99 to 53.01) |
| Week 40 | 38.1 (24.51 to 51.68) | 39.3 (27.46 to 51.11) | 33.3 (17.73 to 48.93) |
| Week 44 | 35.0 (21.33 to 48.67) | 44.8 (32.99 to 56.66) | 37.5 (21.99 to 53.01) |
| Week 48 | 33.3 (20.15 to 46.52) | 35.7 (24.11 to 47.32) | 37.5 (21.99 to 53.01) |
| Week 52 | 33.3 (20.15 to 46.52) | 46.4 (34.35 to 58.51) | 37.5 (21.99 to 53.01) |
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a loss in BCVA letter score from baseline indicates worsening in visual acuity. This analysis was performed on observed data.
| Participants | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W |
|---|---|---|---|
| Day 7: Not Losing ≥15 Letters | 24 | 31 | 16 |
| Day 7: Not Losing ≥10 Letters | 24 | 31 | 16 |
| Day 7: Not Losing ≥5 Letters | 21 | 29 | 15 |
| Day 7: Not Losing ≥0 Letters | 18 | 24 | 10 |
| Week 4: Not Losing ≥15 Letters | 24 | 31 | 16 |
| Week 4: Not Losing ≥10 Letters | 24 | 31 | 16 |
| Week 4: Not Losing ≥5 Letters | 23 | 31 | 16 |
| Week 4: Not Losing ≥0 Letters | 18 | 29 | 13 |
| Week 8: Not Losing ≥15 Letters | 23 | 30 | 15 |
| Week 8: Not Losing ≥10 Letters | 23 | 30 | 15 |
| Week 8: Not Losing ≥5 Letters | 22 | 29 | 15 |
| Week 8: Not Losing ≥0 Letters | 20 | 28 | 13 |
| Week 12: Not Losing ≥15 Letters | 23 | 29 | 16 |
| Week 12: Not Losing ≥10 Letters | 23 | 29 | 16 |
| Week 12: Not Losing ≥5 Letters | 23 | 29 | 16 |
| Week 12: Not Losing ≥0 Letters | 19 | 28 | 14 |
| Week 16: Not Losing ≥15 Letters | 23 | 29 | 16 |
| Week 16: Not Losing ≥10 Letters | 23 | 29 | 16 |
| Week 16: Not Losing ≥5 Letters | 22 | 29 | 16 |
| Week 16: Not Losing ≥0 Letters | 19 | 29 | 16 |
| Week 20: Not Losing ≥15 Letters | 23 | 29 | 16 |
| Week 20: Not Losing ≥10 Letters | 23 | 29 | 16 |
| Week 20: Not Losing ≥5 Letters | 22 | 29 | 16 |
| Week 20: Not Losing ≥0 Letters | 19 | 24 | 14 |
| Week 24: Not Losing ≥15 Letters | 23 | 30 | 16 |
| Week 24: Not Losing ≥10 Letters | 22 | 29 | 16 |
| Week 24: Not Losing ≥5 Letters | 22 | 28 | 16 |
| Week 24: Not Losing ≥0 Letters | 19 | 27 | 14 |
| Week 28: Not Losing ≥15 Letters | 23 | 29 | 16 |
| Week 28: Not Losing ≥10 Letters | 23 | 28 | 16 |
| Week 28: Not Losing ≥5 Letters | 21 | 28 | 16 |
| Week 28: Not Losing ≥0 Letters | 20 | 27 | 16 |
| Week 32: Not Losing ≥15 Letters | 23 | 29 | 16 |
| Week 32: Not Losing ≥10 Letters | 23 | 28 | 16 |
| Week 32: Not Losing ≥5 Letters | 22 | 28 | 16 |
| Week 32: Not Losing ≥0 Letters | 20 | 28 | 13 |
| Week 36: Not Losing ≥15 Letters | 21 | 28 | 16 |
| Week 36: Not Losing ≥10 Letters | 21 | 28 | 16 |
| Week 36: Not Losing ≥5 Letters | 20 | 27 | 15 |
| Week 36: Not Losing ≥0 Letters | 19 | 25 | 14 |
| Week 40: Not Losing ≥15 Letters | 20 | 27 | 15 |
| Week 40: Not Losing ≥10 Letters | 20 | 27 | 15 |
| Week 40: Not Losing ≥5 Letters | 19 | 27 | 15 |
| Week 40: Not Losing ≥0 Letters | 17 | 25 | 12 |
| Week 44: Not Losing ≥15 Letters | 20 | 28 | 16 |
| Week 44: Not Losing ≥10 Letters | 20 | 28 | 16 |
| Week 44: Not Losing ≥5 Letters | 17 | 28 | 16 |
| Week 44: Not Losing ≥0 Letters | 14 | 27 | 12 |
| Week 48: Not Losing ≥15 Letters | 21 | 27 | 16 |
| Week 48: Not Losing ≥10 Letters | 20 | 27 | 16 |
| Week 48: Not Losing ≥5 Letters | 19 | 27 | 15 |
| Week 48: Not Losing ≥0 Letters | 16 | 25 | 11 |
| Week 52: Not Losing ≥15 Letters | 21 | 27 | 16 |
| Week 52: Not Losing ≥10 Letters | 21 | 27 | 16 |
| Week 52: Not Losing ≥5 Letters | 20 | 27 | 15 |
| Week 52: Not Losing ≥0 Letters | 16 | 26 | 11 |
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
| Percentage of participants | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W |
|---|---|---|---|
| Day 7 | 100.0 (100.00 to 100.00) | 100.0 (100.00 to 100.00) | 100.0 (100.00 to 100.00) |
| Week 4 | 100.0 (100.00 to 100.00) | 100.0 (100.00 to 100.00) | 100.0 (100.00 to 100.00) |
| Week 8 | 95.8 (90.61 to 100.00) | 100.0 (100.00 to 100.00) | 100.0 (100.00 to 100.00) |
| Week 12 | 100.0 (100.00 to 100.00) | 96.7 (92.47 to 100.00) | 100.0 (100.00 to 100.00) |
| Week 16 | 100.0 (100.00 to 100.00) | 96.7 (92.47 to 100.00) | 100.0 (100.00 to 100.00) |
| Week 20 | 100.0 (100.00 to 100.00) | 96.7 (92.47 to 100.00) | 100.0 (100.00 to 100.00) |
| Week 24 | 100.0 (100.00 to 100.00) | 100.0 (100.00 to 100.00) | 100.0 (100.00 to 100.00) |
| Week 28 | 100.0 (100.00 to 100.00) | 96.7 (92.47 to 100.00) | 100.0 (100.00 to 100.00) |
| Week 32 | 100.0 (100.00 to 100.00) | 96.7 (92.47 to 100.00) | 100.0 (100.00 to 100.00) |
| Week 36 | 95.5 (89.76 to 100.00) | 96.6 (92.21 to 100.00) | 100.0 (100.00 to 100.00) |
| Week 40 | 95.2 (89.28 to 100.00) | 96.4 (91.93 to 100.00) | 100.0 (100.00 to 100.00) |
| Week 44 | 100.0 (100.00 to 100.00) | 96.6 (92.21 to 100.00) | 100.0 (100.00 to 100.00) |
| Week 48 | 100.0 (100.00 to 100.00) | 96.4 (91.93 to 100.00) | 100.0 (100.00 to 100.00) |
| Week 52 | 100.0 (100.00 to 100.00) | 96.4 (91.93 to 100.00) | 100.0 (100.00 to 100.00) |
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
| Percentage of participants | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W |
|---|---|---|---|
| Baseline | 12.5 (3.85 to 21.15) | 22.6 (12.96 to 32.20) | 18.8 (6.24 to 31.26) |
| Day 7 | 20.8 (10.21 to 31.46) | 45.2 (33.71 to 56.62) | 18.8 (6.24 to 31.26) |
| Week 4 | 45.8 (32.80 to 58.87) | 51.6 (40.11 to 63.12) | 25.0 (11.13 to 38.87) |
| Week 8 | 41.7 (28.77 to 54.56) | 70.0 (59.28 to 80.72) | 20.0 (6.76 to 33.24) |
| Week 12 | 43.5 (30.23 to 56.73) | 73.3 (62.99 to 83.68) | 31.3 (16.40 to 46.10) |
| Week 16 | 52.2 (38.83 to 65.52) | 70.0 (59.28 to 80.72) | 43.8 (27.86 to 59.64) |
| Week 20 | 47.8 (34.48 to 61.17) | 73.3 (62.99 to 83.68) | 50.0 (33.98 to 66.02) |
| Week 24 | 56.5 (43.27 to 69.77) | 70.0 (59.28 to 80.72) | 37.5 (21.99 to 53.01) |
| Week 28 | 56.5 (43.27 to 69.77) | 73.3 (62.99 to 83.68) | 37.5 (21.99 to 53.01) |
| Week 32 | 60.9 (47.83 to 73.91) | 70.0 (59.28 to 80.72) | 43.8 (27.86 to 59.64) |
| Week 36 | 59.1 (45.66 to 72.52) | 75.9 (65.68 to 86.05) | 43.8 (27.86 to 59.64) |
| Week 40 | 61.9 (48.32 to 75.49) | 78.6 (68.63 to 88.51) | 40.0 (23.79 to 56.21) |
| Week 44 | 50.0 (35.67 to 64.33) | 72.4 (61.78 to 83.05) | 37.5 (21.99 to 53.01) |
| Week 48 | 57.1 (43.30 to 70.98) | 75.0 (64.51 to 85.49) | 37.5 (21.99 to 53.01) |
| Week 52 | 57.1 (43.30 to 70.98) | 71.4 (60.49 to 82.37) | 37.5 (21.99 to 53.01) |
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
| Percentage of participants | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W |
|---|---|---|---|
| Baseline | 8.3 (1.10 to 15.56) | 3.2 (0.00 to 7.29) | 12.5 (1.90 to 23.10) |
| Day 7 | 4.2 (0.00 to 9.39) | 0 (0.00 to 0.00) | 0 (0.00 to 0.00) |
| Week 4 | 4.2 (0.00 to 9.39) | 3.2 (0.00 to 7.29) | 0 (0.00 to 0.00) |
| Week 8 | 8.3 (1.10 to 15.56) | 6.7 (0.83 to 12.50) | 0 (0.00 to 0.00) |
| Week 12 | 4.3 (0.00 to 9.80) | 6.7 (0.83 to 12.50) | 0 (0.00 to 0.00) |
| Week 16 | 4.3 (0.00 to 9.80) | 3.3 (0.00 to 7.53) | 0 (0.00 to 0.00) |
| Week 20 | 4.3 (0.00 to 9.80) | 6.7 (0.83 to 12.50) | 0 (0.00 to 0.00) |
| Week 24 | 4.3 (0.00 to 9.80) | 6.7 (0.83 to 12.50) | 0 (0.00 to 0.00) |
| Week 28 | 4.3 (0.00 to 9.80) | 3.3 (0.00 to 7.53) | 0 (0.00 to 0.00) |
| Week 32 | 4.3 (0.00 to 9.80) | 3.3 (0.00 to 7.53) | 0 (0.00 to 0.00) |
| Week 36 | 4.5 (0.00 to 10.24) | 3.4 (0.00 to 7.79) | 0 (0.00 to 0.00) |
| Week 40 | 0 (0.00 to 0.00) | 3.6 (0.00 to 8.07) | 0 (0.00 to 0.00) |
| Week 44 | 5.0 (0.00 to 11.25) | 3.4 (0.00 to 7.79) | 0 (0.00 to 0.00) |
| Week 48 | 4.8 (0.00 to 10.72) | 3.6 (0.00 to 8.07) | 0 (0.00 to 0.00) |
| Week 52 | 4.8 (0.00 to 10.72) | 3.6 (0.00 to 8.07) | 0 (0.00 to 0.00) |
Central foveal thickness (CFT) was defined as the thickness from the inner limiting membrane to the retinal pigment epithelial at the horizontal slice closest to the center of the fovea, and it was measured using spectral domain optical coherence tomography (SD-OCT). The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline CFT.
| microns (μm) | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W |
|---|---|---|---|
| Day 7 | -93.56 (-109.05 to -78.07) | -94.31 (-107.78 to -80.83) | -76.01 (-95.07 to -56.95) |
| Week 4 | -132.27 (-146.13 to -118.41) | -130.11 (-142.37 to -117.85) | -122.07 (-139.47 to -104.67) |
| Week 8 | -134.47 (-148.30 to -120.65) | -136.15 (-148.42 to -123.89) | -127.64 (-145.03 to -110.24) |
| Week 12 | -142.26 (-157.01 to -127.52) | -139.63 (-152.66 to -126.59) | -126.63 (-145.03 to -108.24) |
| Week 16 | -134.94 (-150.26 to -119.63) | -137.81 (-151.37 to -124.25) | -120.48 (-139.55 to -101.40) |
| Week 20 | -125.05 (-143.75 to -106.35) | -125.35 (-141.86 to -108.84) | -120.70 (-143.69 to -97.70) |
| Week 24 | -121.13 (-140.94 to -101.31) | -108.66 (-126.14 to -91.17) | -131.29 (-155.62 to -106.96) |
| Week 28 | -131.58 (-148.18 to -114.99) | -116.76 (-131.41 to -102.12) | -130.29 (-150.80 to -109.78) |
| Week 32 | -127.85 (-149.31 to -106.38) | -123.44 (-142.37 to -104.51) | -134.29 (-160.61 to -107.97) |
| Week 36 | -114.27 (-134.82 to -93.71) | -114.97 (-133.02 to -96.92) | -149.26 (-174.17 to -124.35) |
| Week 40 | -137.54 (-156.68 to -118.40) | -123.31 (-140.20 to -106.42) | -137.99 (-161.27 to -114.71) |
| Week 44 | -135.30 (-154.78 to -115.82) | -110.26 (-127.23 to -93.30) | -135.70 (-159.16 to -112.23) |
| Week 48 | -125.93 (-145.69 to -106.17) | -121.67 (-139.07 to -104.26) | -130.76 (-154.93 to -106.58) |
| Week 52 | -140.95 (-157.06 to -124.85) | -134.99 (-149.21 to -120.76) | -136.10 (-155.98 to -116.23) |
Central subfield thickness (CST) was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 millimetre (mm) central subfield, and it was measured using spectral domain optical coherence tomography (SD-OCT). The analysis was performed using a Mixed Model for Repeated Measurement (MMRM) model, which included an unstructured covariance and the categorical covariates of treatment group, visit, and visit by treatment group interaction and the continuous covariate of baseline CST.
| microns (μm) | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W |
|---|---|---|---|
| Day 7 | -88.87 (-100.40 to -77.34) | -84.23 (-94.35 to -74.11) | -80.08 (-94.15 to -66.01) |
| Week 4 | -127.20 (-139.69 to -114.72) | -123.10 (-134.18 to -112.02) | -111.58 (-126.99 to -96.17) |
| Week 8 | -132.03 (-145.40 to -118.67) | -131.25 (-143.13 to -119.37) | -117.04 (-133.54 to -100.53) |
| Week 12 | -134.70 (-148.96 to -120.44) | -132.87 (-145.53 to -120.20) | -122.39 (-139.93 to -104.85) |
| Week 16 | -132.96 (-147.69 to -118.23) | -132.50 (-145.58 to -119.42) | -122.70 (-140.81 to -104.60) |
| Week 20 | -114.97 (-131.83 to -98.12) | -118.89 (-133.77 to -104.00) | -120.77 (-141.28 to -100.25) |
| Week 24 | -101.62 (-119.69 to -83.54) | -99.35 (-115.29 to -83.42) | -121.33 (-143.26 to -99.40) |
| Week 28 | -129.68 (-144.40 to -114.95) | -109.89 (-122.91 to -96.87) | -127.95 (-145.93 to -109.98) |
| Week 32 | -121.10 (-139.50 to -102.71) | -116.35 (-132.57 to -100.14) | -127.20 (-149.56 to -104.85) |
| Week 36 | -101.98 (-121.60 to -82.36) | -102.69 (-119.96 to -85.42) | -118.89 (-142.63 to -95.15) |
| Week 40 | -138.55 (-154.04 to -123.05) | -121.34 (-135.07 to -107.62) | -126.32 (-145.20 to -107.44) |
| Week 44 | -130.50 (-146.19 to -114.81) | -103.31 (-117.04 to -89.57) | -124.89 (-143.71 to -106.08) |
| Week 48 | -126.45 (-145.58 to -107.33) | -102.30 (-119.14 to -85.47) | -123.89 (-147.01 to -100.77) |
| Week 52 | -138.53 (-152.42 to -124.65) | -122.53 (-134.81 to -110.25) | -129.89 (-146.74 to -113.04) |
The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Intraretinal fluid was defined as the presence of fluid within the retina. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
| Percentage of participants | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W |
|---|---|---|---|
| Baseline | 4.2 (0.00 to 9.39) | 29.0 (18.58 to 39.48) | 18.8 (6.24 to 31.26) |
| Day 7 | 21.7 (10.72 to 32.76) | 38.7 (27.50 to 49.92) | 25.0 (11.13 to 38.87) |
| Week 4 | 29.2 (17.28 to 41.06) | 48.4 (36.88 to 59.89) | 50.0 (33.98 to 66.02) |
| Week 8 | 33.3 (21.00 to 45.67) | 46.7 (34.99 to 58.34) | 26.7 (12.03 to 41.30) |
| Week 12 | 39.1 (26.09 to 52.17) | 43.3 (31.74 to 54.93) | 37.5 (21.99 to 53.01) |
| Week 16 | 47.8 (34.48 to 61.17) | 50.0 (38.30 to 61.70) | 37.5 (21.99 to 53.01) |
| Week 20 | 43.5 (30.23 to 56.73) | 53.3 (41.66 to 65.01) | 18.8 (6.24 to 31.26) |
| Week 24 | 30.4 (18.14 to 42.73) | 50.0 (38.30 to 61.70) | 31.3 (16.40 to 46.10) |
| Week 28 | 26.1 (14.35 to 37.82) | 53.3 (41.66 to 65.01) | 31.3 (16.40 to 46.10) |
| Week 32 | 26.1 (14.35 to 37.82) | 50.0 (38.30 to 61.70) | 31.3 (16.40 to 46.10) |
| Week 36 | 31.8 (19.09 to 44.54) | 44.8 (32.99 to 56.66) | 37.5 (21.99 to 53.01) |
| Week 40 | 38.1 (24.51 to 51.68) | 57.1 (45.16 to 69.13) | 33.3 (17.73 to 48.93) |
| Week 44 | 55.0 (40.74 to 69.26) | 48.3 (36.38 to 60.17) | 43.8 (27.86 to 59.64) |
| Week 48 | 38.1 (24.51 to 51.68) | 53.6 (41.49 to 65.65) | 62.5 (46.99 to 78.01) |
| Week 52 | 38.1 (24.51 to 51.68) | 35.7 (24.11 to 47.32) | 62.5 (46.99 to 78.01) |
The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Subretinal fluid was defined as the presence of fluid between the retina and the retinal pigment epithelium. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
| Percentage of participants | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W |
|---|---|---|---|
| Baseline | 20.8 (10.21 to 31.46) | 12.9 (5.19 to 20.62) | 25.0 (11.13 to 38.87) |
| Day 7 | 39.1 (26.09 to 52.17) | 29.0 (18.58 to 39.48) | 31.3 (16.40 to 46.10) |
| Week 4 | 70.8 (58.94 to 82.72) | 77.4 (67.80 to 87.04) | 62.5 (46.99 to 78.01) |
| Week 8 | 83.3 (73.58 to 93.08) | 86.7 (78.71 to 94.62) | 80.0 (66.76 to 93.24) |
| Week 12 | 91.3 (83.77 to 98.83) | 90.0 (82.98 to 97.02) | 75.0 (61.13 to 88.87) |
| Week 16 | 87.0 (77.96 to 95.96) | 96.7 (92.47 to 100.00) | 75.0 (61.13 to 88.87) |
| Week 20 | 69.6 (57.27 to 81.86) | 70.0 (59.28 to 80.72) | 87.5 (76.90 to 98.10) |
| Week 24 | 65.2 (52.49 to 77.94) | 66.7 (55.64 to 77.70) | 75.0 (61.13 to 88.87) |
| Week 28 | 91.3 (83.77 to 98.83) | 70.0 (59.28 to 80.72) | 75.0 (61.13 to 88.87) |
| Week 32 | 69.6 (57.27 to 81.86) | 80.0 (70.64 to 89.36) | 68.8 (53.90 to 83.60) |
| Week 36 | 68.2 (55.46 to 80.91) | 72.4 (61.78 to 83.05) | 81.3 (68.74 to 93.76) |
| Week 40 | 81.0 (69.97 to 91.93) | 89.3 (81.79 to 96.78) | 86.7 (75.42 to 97.91) |
| Week 44 | 80.0 (68.54 to 91.46) | 75.9 (65.68 to 86.05) | 81.3 (68.74 to 93.76) |
| Week 48 | 71.4 (58.79 to 84.06) | 64.3 (52.68 to 75.89) | 87.5 (76.90 to 98.10) |
| Week 52 | 81.0 (69.97 to 91.93) | 89.3 (81.79 to 96.78) | 87.5 (76.90 to 98.10) |
The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Cysts were defined as the presence of cystoid space (fluid) in the retina. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
| Percentage of participants | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W |
|---|---|---|---|
| Baseline | 33.3 (21.00 to 45.67) | 48.4 (36.88 to 59.89) | 37.5 (21.99 to 53.01) |
| Day 7 | 65.2 (52.49 to 77.94) | 83.9 (75.41 to 92.34) | 75.0 (61.13 to 88.87) |
| Week 4 | 87.5 (78.85 to 96.15) | 87.1 (79.38 to 94.81) | 87.5 (76.90 to 98.10) |
| Week 8 | 83.3 (73.58 to 93.08) | 83.3 (74.61 to 92.05) | 86.7 (75.42 to 97.91) |
| Week 12 | 91.3 (83.77 to 98.83) | 83.3 (74.61 to 92.05) | 68.8 (53.90 to 83.60) |
| Week 16 | 91.3 (83.77 to 98.83) | 83.3 (74.61 to 92.05) | 75.0 (61.13 to 88.87) |
| Week 20 | 91.3 (83.77 to 98.83) | 80.0 (70.64 to 89.36) | 68.8 (53.90 to 83.60) |
| Week 24 | 73.9 (62.18 to 85.65) | 76.7 (66.77 to 86.56) | 68.8 (53.90 to 83.60) |
| Week 28 | 95.7 (90.20 to 100.00) | 70.0 (59.28 to 80.72) | 68.8 (53.90 to 83.60) |
| Week 32 | 82.6 (72.48 to 92.74) | 76.7 (66.77 to 86.56) | 75.0 (61.13 to 88.87) |
| Week 36 | 77.3 (65.82 to 88.72) | 79.3 (69.67 to 88.95) | 68.8 (53.90 to 83.60) |
| Week 40 | 85.7 (75.93 to 95.50) | 78.6 (68.63 to 88.51) | 80.0 (66.76 to 93.24) |
| Week 44 | 100.0 (100.00 to 100.00) | 72.4 (61.78 to 83.05) | 87.5 (76.90 to 98.10) |
| Week 48 | 95.2 (89.28 to 100.00) | 85.7 (77.24 to 94.19) | 87.5 (76.90 to 98.10) |
| Week 52 | 100.0 (100.00 to 100.00) | 78.6 (68.63 to 88.51) | 87.5 (76.90 to 98.10) |
The absence of intraretinal fluid, subretinal fluid, cysts, or pigment epithelial detachment, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Pigment epithelial detachment was defined as the presence of a detachment of the pigment epithelium from the Bruch's membrane. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis was performed on observed data. The 80% confidence intervals were calculated using the Wald method.
| Percentage of participants | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W |
|---|---|---|---|
| Baseline | 8.3 (1.10 to 15.56) | 29.0 (18.58 to 39.48) | 12.5 (1.90 to 23.10) |
| Day 7 | 13.0 (4.04 to 22.04) | 29.0 (18.58 to 39.48) | 12.5 (1.90 to 23.10) |
| Week 4 | 8.3 (1.10 to 15.56) | 22.6 (12.96 to 32.20) | 12.5 (1.90 to 23.10) |
| Week 8 | 8.3 (1.10 to 15.56) | 23.3 (13.44 to 33.23) | 13.3 (2.09 to 24.58) |
| Week 12 | 8.7 (1.17 to 16.23) | 26.7 (16.32 to 37.01) | 12.5 (1.90 to 23.10) |
| Week 16 | 8.7 (1.17 to 16.23) | 23.3 (13.44 to 33.23) | 12.5 (1.90 to 23.10) |
| Week 20 | 13.0 (4.04 to 22.04) | 23.3 (13.44 to 33.23) | 12.5 (1.90 to 23.10) |
| Week 24 | 13.0 (4.04 to 22.04) | 23.3 (13.44 to 33.23) | 12.5 (1.90 to 23.10) |
| Week 28 | 13.0 (4.04 to 22.04) | 20.0 (10.64 to 29.36) | 12.5 (1.90 to 23.10) |
| Week 32 | 13.0 (4.04 to 22.04) | 23.3 (13.44 to 33.23) | 12.5 (1.90 to 23.10) |
| Week 36 | 4.5 (0.00 to 10.24) | 20.7 (11.05 to 30.33) | 12.5 (1.90 to 23.10) |
| Week 40 | 4.8 (0.00 to 10.72) | 21.4 (11.49 to 31.37) | 13.3 (2.09 to 24.58) |
| Week 44 | 5.0 (0.00 to 11.25) | 17.2 (8.25 to 26.23) | 12.5 (1.90 to 23.10) |
| Week 48 | 9.5 (1.31 to 17.73) | 17.9 (8.58 to 27.13) | 12.5 (1.90 to 23.10) |
| Week 52 | 14.3 (4.50 to 24.07) | 14.3 (5.81 to 22.76) | 12.5 (1.90 to 23.10) |
The total area of choroidal neovascularization (CNV) was evaluated by a central reading center using fundus fluorescein angiography (FFA).
| millimetres squared (mm^2) | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W |
|---|---|---|---|
| Baseline (BL): Absolute Value | 7.1 ± 3.9 | 5.9 ± 3.8 | 7.3 ± 2.9 |
| Change from BL at Week 40 | -4.7 ± 4.3 | -3.9 ± 3.7 | -4.6 ± 3.5 |
| Change from BL at Week 52 | -5.4 ± 4.0 | -4.2 ± 3.4 | -4.5 ± 3.2 |
The total area of choroidal neovascularization (CNV) component (i.e., total area of CNV membrane) was evaluated by a central reading center using fundus fluorescein angiography (FFA).
| millimetres squared (mm^2) | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W |
|---|---|---|---|
| Baseline (BL): Absolute Value | 7.0 ± 3.8 | 5.8 ± 3.6 | 7.1 ± 3.0 |
| Change from BL at Week 40 | -5.0 ± 4.2 | -4.0 ± 4.0 | -4.7 ± 3.4 |
| Change from BL at Week 52 | -5.6 ± 4.0 | -4.3 ± 3.7 | -4.8 ± 3.2 |
The total area of leakage was evaluated by a central reading center using fundus fluorescein angiography (FFA).
| millimetres squared (mm^2) | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W |
|---|---|---|---|
| Baseline (BL): Absolute Value | 7.0 ± 3.8 | 6.1 ± 3.4 | 7.6 ± 2.9 |
| Change from BL at Week 40 | -5.0 ± 4.2 | -4.3 ± 3.9 | -5.3 ± 3.7 |
| Change from BL at Week 52 | -5.6 ± 4.0 | -4.6 ± 3.5 | -5.3 ± 3.5 |
Blood samples were obtained for measurement of anti-drug antibodies (ADAs) to faricimab by a validated enzyme-linked immunosorbent assay (ELISA).
| Participants | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W |
|---|---|---|
| ADA Negative to ADA Negative | 21 | 25 |
| ADA Negative to ADA Positive | 1 | 4 |
| Missing to ADA Negative | 0 | 1 |
| Missing to ADA Positive | 1 | 0 |
| No Post-Baseline ADA Assessment | 1 | 1 |
This safety summary reports the number and percentage of participants who experienced at least one adverse event (AE) during the study. The investigator independently assessed the seriousness and severity for each AE. Severity was graded according to the following grading scale: Mild = Discomfort noticed, but no disruption of normal daily activity; Moderate = Discomfort sufficient to reduce or affect normal daily activity; Severe = Incapacitating with inability to work or to perform normal daily activity. Severity and seriousness are not synonymous; regardless of severity, some AEs may have also met seriousness criteria.
| Participants | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W |
|---|---|---|---|
| Any Adverse Event (AE) | 18 | 23 | 13 |
| Serious AE (SAE) | 4 | 3 | 0 |
| SAE Leading to Withdrawal from Treatment | 0 | 0 | 0 |
| SAE Leading to Dose Modification/Interruption | 1 | 0 | 0 |
| Serious Ocular AE | 0 | 0 | 0 |
| Serious Non-Ocular AE | 4 | 3 | 0 |
| AE Leading to Withdrawal from Treatment | 0 | 0 | 0 |
| AE Leading to Dose Modification/Interruption | 2 | 0 | 0 |
| Ocular AE in the Study Eye | 9 | 11 | 8 |
| Ocular AE in the Fellow Eye | 6 | 5 | 6 |
| Non-Ocular AE | 14 | 20 | 9 |
Collected over From Baseline until 28 days after the last dose of study drug (up to 52 weeks). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 6 mg Faricimab Q12W | 1/24 (4.2%) | 4/24 (16.7%) | 18/24 (75%) |
| 6 mg Faricimab Q16W | 2/31 (6.5%) | 3/31 (9.7%) | 22/31 (71%) |
| 0.5 mg Ranibizumab Q4W | 0/16 (0%) | 0/16 (0%) | 13/16 (81.3%) |
| Event | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W |
|---|---|---|---|
| Acute left ventricular failureCardiac disorders | 1/24 | 0/31 | 0/16 |
| Coronary artery diseaseCardiac disorders | 1/24 | 0/31 | 0/16 |
| VertigoEar and labyrinth disorders | 1/24 | 0/31 | 0/16 |
| FallInjury, poisoning and procedural complications | 1/24 | 0/31 | 0/16 |
| HeadacheNervous system disorders | 1/24 | 0/31 | 0/16 |
| Ischaemic strokeNervous system disorders | 1/24 | 0/31 | 0/16 |
| Mental status changesPsychiatric disorders | 1/24 | 0/31 | 0/16 |
| Atrial fibrillationCardiac disorders | 0/24 | 1/31 | 0/16 |
| SepsisInfections and infestations | 0/24 | 1/31 | 0/16 |
| Metastatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/24 | 1/31 | 0/16 |
| Event | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W |
|---|---|---|---|
| Conjunctival haemorrhageEye disorders | 5/24 | 4/31 | 4/16 |
| NasopharyngitisInfections and infestations | 4/24 | 2/31 | 1/16 |
| FallInjury, poisoning and procedural complications | 0/24 | 5/31 | 1/16 |
| Neovascular age-related macular degenerationEye disorders | 3/24 | 0/31 | 2/16 |
| Eye painEye disorders | 2/24 | 0/31 | 2/16 |
| Retinal haemorrhageEye disorders | 2/24 | 0/31 | 2/16 |
| CataractEye disorders | 2/24 | 1/31 | 0/16 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/24 | 0/31 | 0/16 |
| MaculopathyEye disorders | 0/24 | 2/31 | 0/16 |
| Urinary tract infectionInfections and infestations | 1/24 | 2/31 | 1/16 |
The efficacy population includes randomized participants grouped according to their assigned treatment. A total of 76 patients were randomized in the study, but 5 participants in total (all randomized to the 6 mg Faricimab Q12W Arm) were excluded from the analysis populations because of Good Clinical Practice (GCP) violations at a single site.
| Age, Continuous(Years) | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W | Total |
|---|---|---|---|---|
| Mean | 80.3 ± 7.23 | 77.7 ± 8.38 | 77.3 ± 10.29 | 78.5 ± 8.47 |
| Sex: Female, Male(Participants) | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W | Total |
|---|---|---|---|---|
| Female | 13 | 18 | 10 | 41 |
| Male | 11 | 13 | 6 | 30 |
| Ethnicity (NIH/OMB)(Participants) | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 23 | 31 | 16 | 70 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W | Total |
|---|---|---|---|---|
| Asian | 0 | 1 | 0 | 1 |
| Black or African American | 1 | 0 | 0 | 1 |
| White | 23 | 30 | 16 | 69 |
| Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye at Baseline(ETDRS Letters) | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W | Total |
|---|---|---|---|---|
| Mean | 57.8 ± 10.46 | 60.4 ± 10.80 | 55.3 ± 12.08 | 58.4 ± 11.02 |
| Choroidal Neovascularization (CNV) Lesion Type in the Study Eye at Baseline(Participants) | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W | Total |
|---|---|---|---|---|
| Classic and Occult CNV | 0 | 2 | 2 | 4 |
| Classic CNV | 9 | 9 | 6 | 24 |
| Occult CNV | 15 | 20 | 8 | 43 |
| Central Foveal Thickness in the Study Eye at Baseline(microns (μm)) | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W | Total |
|---|---|---|---|---|
| Mean | 290.8 ± 118.61 | 280.8 ± 98.95 | 375.6 ± 159.41 | 305.6 ± 125.42 |
| Central Subfield Thickness in the Study Eye at Baseline(microns (μm)) | 6 mg Faricimab Q12W | 6 mg Faricimab Q16W | 0.5 mg Ranibizumab Q4W | Total |
|---|---|---|---|---|
| Mean | 417.9 ± 84.28 | 382.2 ± 80.87 | 443.1 ± 125.00 | 408.0 ± 95.36 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2017 to primary completion in Jan 2018, 11 months.
Results were first posted in Jan 2021, 2 years 11 months after primary completion. A results delay was requested in Jan 2019.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Faricimab
Choroidal Neovascularization →